1310 ET - Kyndryl dives after a tough F1Q for revenue, but the weakness looks like a good buying opportunity for bullish analysts at Oppenheimer who expect the company to return to organic growth next quarter. Constant currency revenue was down 2.6% from signing delays at a handful of large focus accounts, the analysts say. But management believes those delays are esoteric rather than related to broader macro problems, and that organic growth should return in F2Q, the analysts say. Management also maintained FY26 guidance that calls for constant currency revenue growth of 1%, they say. Kyndryl tumbles 21% at $29.14. (dean.seal@wsj.com)

(END) Dow Jones Newswires

August 05, 2025 13:10 ET (17:10 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.